Details for New Drug Application (NDA): 218015
✉ Email this page to a colleague
The generic ingredient in LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; losartan potassium. There are thirty-two drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.
Summary for 218015
Tradename: | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
Applicant: | Granules |
Ingredient: | hydrochlorothiazide; losartan potassium |
Patents: | 0 |
Pharmacology for NDA: 218015
Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Physiological Effect | Increased Diuresis |
Suppliers and Packaging for NDA: 218015
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; losartan potassium | TABLET;ORAL | 218015 | ANDA | Granules Pharmaceuticals Inc. | 70010-187 | 70010-187-03 | 30 TABLET, FILM COATED in 1 BOTTLE (70010-187-03) |
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; losartan potassium | TABLET;ORAL | 218015 | ANDA | Granules Pharmaceuticals Inc. | 70010-187 | 70010-187-10 | 1000 TABLET, FILM COATED in 1 BOTTLE (70010-187-10) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 12.5MG;50MG | ||||
Approval Date: | Sep 29, 2023 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 12.5MG;100MG | ||||
Approval Date: | Sep 29, 2023 | TE: | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;100MG | ||||
Approval Date: | Sep 29, 2023 | TE: | RLD: | No |
Complete Access Available with Subscription